2026-05-20T03:47:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/265642025-12-18T13:01:28Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16963col_20.500.12105_16978

00925njm 22002777a 4500 dc Sepulveda-Crespo, Daniel author Volpi, Camilla author Amigot-Sánchez, Rafael author Yélamos, María Belén author Díez, Cristina author Gómez, Julián author Hontañón, Víctor author Berenguer, Juan author González-García, Juan author Martín-Escolano, Rubén author Resino, Salvador author Martinez, Isidoro author 2024-08-30 Background: This study evaluated titers and amplitudes of anti-E2 antibodies (anti-E2-Abs) and neutralizing antibodies against hepatitis C virus (HCV; anti-HCV-nAbs) in HIV/HCV-coinfected individuals over five years after successful HCV treatment completion. Methods: We retrospectively analyzed 76 HIV/HCV-coinfected patients achieving sustained virologic response post-HCV treatment. Plasma levels of anti-E2-Abs and anti-HCV-nAbs against five HCV genotypes (Gt1a, Gt1b, Gt2a, Gt3a, and Gt4a) were determined using ELISA and microneutralization assays, respectively. Statistical analyses comparing the three follow-up time points (baseline, one year, and five years post-HCV treatment) were performed using generalized linear mixed models, adjusting p-values with the false discovery rate (q-value). Results: Compared to baseline, anti-E2-Abs titers decreased at one year (1.9- to 2.3-fold, q-value < 0.001) and five years (3.4- to 9.1-fold, q-value < 0.001) post-HCV treatment. Anti-HCV-nAbs decreased 2.9- to 8.4-fold (q-value < 0.002) at one year and 17.8- to 90.4-fold (q-value < 0.001) at five years post-HCV treatment. Anti-HCV-nAbs titers against Gt3a were consistently the lowest. Nonresponse rates for anti-E2-Abs remained low throughout the follow-up, while anti-HCV-nAbs nonresponse rates increased 1.8- to 13.5-fold (q-value < 0.05) at five years post-HCV treatment, with Gt3a showing the highest nonresponse rate. Conclusions: Humoral immune responses against HCV decreased consistently one and five years post-HCV treatment, regardless of HCV genotype and previous HCV therapy or type of treatment (IFN- or DAA-based therapy). This decline was more pronounced for anti-HCV-nAbs, particularly against Gt3. Sepúlveda-Crespo D, Volpi C, Amigot-Sánchez R, Yélamos MB, Díez C, Gómez J, Hontañón V, Berenguer J, González-García J, Martín-Escolano R, Resino S, Martínez I. Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study. Pharmaceuticals (Basel). 2024 Aug 30;17(9):1152. 10.3390/ph17091152 1424-8247 Pharmaceuticals (Basel) 39338314 https://hdl.handle.net/20.500.12105/26564 HIV HIV/HCV coinfection Anti-HCV therapy Broad-spectrum neutralizing antibodies Hepatitis C Sustained virologic response Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study